Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data.

BACKGROUND There is no universal consensus on the best staging system for chronic obstructive pulmonary disease (COPD). Although documents (eg, the Global Initiative for Chronic Obstructive Lung Disease [GOLD] 2007) have traditionally used forced expiratory volume in 1 s (FEV1) for staging, clinical parameters have been added to some guidelines (eg, GOLD 2011) to improve patient management. As part of the COPD Cohorts Collaborative International Assessment (3CIA) initiative, we aimed to investigate how individual patients were categorised by GOLD 2007 and 2011, and compare the prognostic accuracy of the staging documents for mortality. METHODS We searched reports published from Jan 1, 2008, to Dec 31, 2014. Using data from cohorts that agreed to participate and had a minimum amount of information needed for GOLD 2007 and 2011, we did a patient-based pooled analysis of existing data. With use of raw data, we recalculated all participant assignments to GOLD 2007 I-IV classes, and GOLD 2011 A-D stages. We used survival analysis, C statistics, and non-parametric regression to model time-to-death data and compare GOLD 2007 and GOLD 2011 staging systems to predict mortality. FINDINGS We collected individual data for 15 632 patients from 22 COPD cohorts from seven countries, totalling 70 184 person-years. Mean age of the patients was 63·9 years (SD 10·1); 10 751 (69%) were men. Based on FEV1 alone (GOLD 2007), 2424 (16%) patients had mild (I), 7142 (46%) moderate (II), 4346 (28%) severe (III), and 1670 (11%) very severe (IV) disease. We compared staging with the GOLD 2007 document with that of the new GOLD 2011 system in 14 660 patients: 5548 (38%) were grade A, 2733 (19%) were grade B, 1835 (13%) were grade C, and 4544 (31%) were grade D. GOLD 2011 shifted the overall COPD severity distribution to more severe categories. There were nearly three times more COPD patients in stage D than in former stage IV (p<0·05). The predictive capacity for survival up to 10 years was significant for both systems (p<0·01) but area under the curves were only 0·623 (GOLD 2007) and 0·634 (GOLD 2011), and GOLD 2007 and 2011 did not differ significantly. We identified the percent predicted FEV1 thresholds of 85%, 55% and 35% as better to stage COPD severity for mortality, which are similar to the ones used previously. INTERPRETATION Neither GOLD COPD classification schemes have sufficient discriminatory power to be used clinically for risk classification at the individual level to predict total mortality for 3 years of follow-up and onwards. Increasing intensity of treatment of patients with COPD due to their GOLD 2011 reclassification is not known to improve health outcomes. Evidence-based thresholds should be searched when exploring the prognostic ability of current and new COPD multicomponent indices. FUNDING None.

[1]  S. Quintana,et al.  Mortality after hospitalization for COPD. , 2002, Chest.

[2]  W. Bailey,et al.  Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution , 2023, Medical science monitor : international medical journal of experimental and clinical research.

[3]  R. Stockley,et al.  Global Initiative for Chronic Obstructive Lung Disease 2011 symptom/risk assessment in α1-antitrypsin deficiency. , 2013, Chest.

[4]  J. Lima,et al.  The effect of airflow limitation on the cause of death in patients with COPD , 2010, Chronic respiratory disease.

[5]  J. Vestbo,et al.  Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. , 1996, American journal of respiratory and critical care medicine.

[6]  B. Brumpton,et al.  GOLD classifications and mortality in chronic obstructive pulmonary disease: the HUNT Study, Norway , 2013, Thorax.

[7]  B. Celli,et al.  Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. , 2005, American journal of respiratory and critical care medicine.

[8]  Nicolas Roche,et al.  Impact of gender on COPD expression in a real-life cohort , 2014, Respiratory Research.

[9]  M. Martínez,et al.  Risk factors of emergency care and admissions in COPD patients with high consumption of health resources. , 2004, Respiratory medicine.

[10]  P. Heagerty,et al.  Survival Model Predictive Accuracy and ROC Curves , 2005, Biometrics.

[11]  Josep Roca,et al.  Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes , 2010, Thorax.

[12]  E. Regan,et al.  Genetic Epidemiology of COPD (COPDGene) Study Design , 2011, COPD.

[13]  J. Soriano,et al.  Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. , 2010, American journal of respiratory and critical care medicine.

[14]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[15]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[16]  Elizabeth J. Malloy,et al.  Comparing measures of model selection for penalized splines in Cox models , 2009, Comput. Stat. Data Anal..

[17]  R. Riley,et al.  Meta-analysis of individual participant data: rationale, conduct, and reporting , 2010, BMJ : British Medical Journal.

[18]  A. Gulsvik,et al.  Comparison of 2011 and 2007 Global Initiative for Chronic Obstructive Lung Disease guidelines for predicting mortality and hospitalization. , 2013, American journal of respiratory and critical care medicine.

[19]  Paul Enright,et al.  Large-scale international validation of the ADO index in subjects with COPD: an individual subject data analysis of 10 cohorts , 2012, BMJ Open.

[20]  Ulrike Held,et al.  Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index , 2009, The Lancet.

[21]  P. Martínez-Camblor,et al.  A general bootstrap algorithm for hypothesis testing , 2012 .

[22]  B. Celli,et al.  Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE , 2014, Thorax.

[23]  J. Soriano,et al.  Recent improvement in long-term survival after a COPD hospitalisation , 2010, Thorax.

[24]  M. Martínez-García,et al.  Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. , 2009, Respiratory medicine.

[25]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[26]  Ciro Casanova,et al.  Finding the Best Thresholds of FEV1 and Dyspnea to Predict 5-Year Survival in COPD Patients: The COCOMICS Study , 2014, PloS one.

[27]  M. Puhan,et al.  Five comorbidities reflected the health status in patients with chronic obstructive pulmonary disease: the newly developed COMCOLD index. , 2014, Journal of clinical epidemiology.

[28]  M. Rodríguez-Carballeira,et al.  Mortalidad posthospitalaria en pacientes reingresadores por EPOC. Utilidad del índice BODE , 2009 .

[29]  M. Martínez-García,et al.  with chronic obstructive pulmonary disease Severe acute exacerbations and mortality in patients , 2006 .

[30]  L. Edwards,et al.  Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort , 2013, European Respiratory Journal.

[31]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[32]  I. Arostegui,et al.  The health, activity, dyspnea, obstruction, age, and hospitalization: prognostic score for stable COPD patients. , 2011, Respiratory medicine.

[33]  Steven Piantadosi,et al.  A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. , 2003, The New England journal of medicine.